Loading...
Arcus Biosciences Q1 2025 Earnings Report
Arcus Biosciences reported its first-quarter 2025 financial results, showing a decrease in revenue and an increase in net loss compared to the same period in 2024, while maintaining a strong cash position.
Key Takeaways
Arcus Biosciences reported a total revenue of $28 million for the first quarter of 2025, a significant decrease from $145 million in the same period of 2024. The company recorded a net loss of $112 million, compared to a net loss of $4 million in Q1 2024. Despite the financial results, Arcus maintained a strong cash position with $1.0 billion in cash, cash equivalents, and marketable securities.
Total revenues for Q1 2025 were $28 million, down from $145 million in Q1 2024.
Net loss for Q1 2025 was $112 million, compared to $4 million in Q1 2024.
Research and Development (R&D) expenses increased to $122 million in Q1 2025 from $109 million in Q1 2024.
Cash, cash equivalents, and marketable securities stood at $1.0 billion as of March 31, 2025.
Revenue by Segment
Forward Guidance
Arcus Biosciences expects to recognize GAAP revenue of between $75 million and $90 million for the full year 2025. The company believes its current cash, cash equivalents, and marketable securities, along with available facilities, will be sufficient to fund operations through initial pivotal readouts for domvanalimab, quemliclustat, and casdatifan, including PEAK-1.
Positive Outlook
- Expects to report a steady stream of data from ARC-20 throughout the remainder of 2025 and into 2026.
- Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in Q2 2025.
- Arcus and AstraZeneca expect to initiate a clinical study evaluating casdatifan plus volrustomig in IO-naive ccRCC shortly after PEAK-1 initiation.
- Enrollment completion for PRISM-1 (quemliclustat in pancreatic cancer) is expected by the end of 2025.
- Overall survival data from the Phase 2 EDGE-Gastric study (domvanalimab plus zimberelimab and chemotherapy) are expected in Fall 2025.
Challenges Ahead
- The company is not pursuing a Phase 3 study for etrumadenant in third-line mCRC at this time, despite promising results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...